drugset / Trial / NCT06026566

Compatible Effect of Remimazolam Besylate Combined With Afentanil for ATI

NCT06026566

Unknown 180 enrolled Tongji Hospital
RandomizedCrossoverSingle-blindTreatment

Summary

1. To study the pharmacokinetics between remimazolam besylate and alfentanil; 2. To determine the optimal dosage of the two drugs in awake endotracheal intubation; 3. To provide clinical guidance for awake endotracheal intubation.

Timeline

Start
2023-04-01
Primary completion
2025-08-31
Completion
2025-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alfentanil Other / unclassified 20 ng/ml
Subject Alfentanil Other / unclassified 30 ng/ml
Subject Alfentanil Other / unclassified 40 ng/ml
Subject Alfentanil Other / unclassified 50 ng/ml
Subject Alfentanil Other / unclassified 60 ng/ml
Subject Alfentanil Other / unclassified 70 ng/ml
Subject Alfentanil Other / unclassified 80 ng/ml
Subject Alfentanil Other / unclassified 90 ng/ml
Subject Alfentanil Other / unclassified 100 ng/ml

Indications

No indication recorded.